Keyword

AMD3100

Description: AMD3100, also known as plerixafor, is a small-molecule CXCR4 antagonist studied for mobilizing hematopoietic cells and modulating inflammatory and disease processes.

Primary topic: Chemokine receptors and signaling (24%)

Wikidata ID: wiki/Q905835

OpenAlex ID: keywords/amd3100

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

2013 · Christine Feig, James O. Jones, et al. · Proceedings of the National Academy of Sciences · 2,090

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

2005 · Hal E. Broxmeyer, Christie M. Orschell, et al. · The Journal of Experimental Medicine · 1,106

PDF

Stromal Cell–Derived Factor-1α Plays a Critical Role in Stem Cell Recruitment to the Heart After Myocardial Infarction but Is Not Sufficient to Induce Homing in the Absence of Injury

2004 · J. Dawn Abbott, Yan Huang, et al. · Circulation · 783

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice

2010 · Mitomu Kioi, Hannes Vogel, et al. · Journal of Clinical Investigation · 773

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

1998 · George A. Donzella, Dominique Schols, et al. · Nature Medicine · 760

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

2003 · W. Conrad Liles, Hal E. Broxmeyer, et al. · Blood · 718

CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer

2004 · Matthew C. P. Smith, Kathryn E. Luker, et al. · Cancer Research · 715

PDF

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

2009 · John F. DiPersio, Ivana N. Micallef, et al. · Journal of Clinical Oncology · 681

HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4

2012 · Milena Schiraldi, Angela Raucci, et al. · The Journal of Experimental Medicine · 676

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors

2003 · Joshua B. Rubin, Andrew L. Kung, et al. · Proceedings of the National Academy of Sciences · 615

Using coordination chemistry to design new medicines

2006 · Luca Ronconi, Peter J. Sadler · Coordination Chemistry Reviews · 608

The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis

2007 · Isabelle Petit, David Jin, et al. · Trends in Immunology · 603

Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4

1997 · Dominique Schols, Sofie Struyf, et al. · The Journal of Experimental Medicine · 554

PDF

Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

2000 · Craig W. Hendrix, Charles Flexner, et al. · Antimicrobial Agents and Chemotherapy · 504

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

2008 · Bruno Nervi, Pablo Ramirez, et al. · Blood · 491

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma

2006 · Yazan Alsayed, Hai Ngo, et al. · Blood · 478

Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.

2002 · Chris J Scotton, Julia L Wilson, et al. · PubMed · 473

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

2005 · N. Flomenberg · Blood · 460

The bicyclam AMD3100 story

2003 · Erik De Clercq · Nature Reviews Drug Discovery · 460

CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice

2014 · Yunching Chen, Rakesh R. Ramjiawan, et al. · Hepatology · 450

PDF

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4

2002 · Sigrid Hatse, Katrien Princen, et al. · FEBS Letters · 450

PDF

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

2009 · Abdel Kareem Azab, Judith M. Runnels, et al. · Blood · 428

Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

2004 · Steven M. Devine, Neal Flomenberg, et al. · Journal of Clinical Oncology · 420

PDF

CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

2011 · Dan G. Duda, Sergey V. Kozin, et al. · Clinical Cancer Research · 396

Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion

2006 · David Zagzag, Yevgeniy Lukyanov, et al. · Laboratory Investigation · 396

Works count: 2,685

Citation count: 83,810